The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Total Health

W. Iams

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical Implicat…

Insights from 2023 ASCO® Annual Meeting

J. West

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

2024 ASCO® Annual Meeting Insights Hub

V. Subbiah

NSCLC & Targeted Therapy: A Brief Overview and Update in the Metasta…

Memorial Sloan Kettering Cancer Center

M. Hwang

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

ecancer

L. Raez

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

2024 Updates on the Fast-Changing NSCLC Landscape

Total Health

R. Osarogiagbon

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Year in Review: Precision Medicine

Vivek Subbiah

ADCs and Bispecific Inhibitors in NSCLC

Chul Kim

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxel in …

2024 ASCO® Annual Meeting Insights Hub

T. Mok

Clinical Implications of Tumor Agnostic Therapies

Shivaani Kummar

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip